Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Biostar to Develop New TCM for Cardiovascular Disease

publication date: Jan 14, 2015
Biostar Pharma, a traditional Chinese medicine company, signed an R&D pact with Northwest University of Xi'an to develop Danshensu Yibingzhi (IDHP), a Class One drug for the treatment of cardiovascular diseases. The university holds patents to IDHP, which was developed by Professor Xiaohui Zheng, who is affiliated with the university and also serves as Chief Scientist at Biostar. The company invests about 18% of its revenues in R&D. More details....

Stock Symbol: (NSDQ: BSPM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital